Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TMS CoTSE:4891 -0.91%32 EV-to-EBIT is -5.49 as of Aug. 25, 2026. GuruFocus rates TSE:4891 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 376 Biotechnology companies, TMS Co ranks worse than 265957.18% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TMS Co's Enterprise Value is 円2,592.13 Mil.
TMS Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was 円-471.93 Mil. Therefore, TMS Co's EV-to-EBIT for today is -5.49.
The historical rank and industry rank for TMS Co's EV-to-EBIT or its related term are showing as below:
TSE:4891'
s EV-to-EBIT Range Over the Past 10 Years
Min: -5.59 Med: 0 Max: 0
Current: -5.49
TSE:4891's EV-to-EBIT is ranked worse than 100% of 376
companies
in the Biotechnology industry
Industry Median: 16.275
vs TSE:4891: -5.49
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
TMS Co's Enterprise Value for the quarter that ended in Jun. 2026 was 円2,518.58 Mil.
TMS Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-471.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMS Co EV-to-EBIT Related Terms
TMS Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for TMS Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4891 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, TMS Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMS Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TMS Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where TMS Co's EV-to-EBIT falls into.
TMS Co's current Enterprise Value is 円2,592.13 Mil.
TMS Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-471.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMS Co (TSE:4891) has a EV-to-EBIT of -5.49 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TMS Co and its competitors. According to the industry distribution chart, TMS Co ranks #999999 out of 376 companies in the Biotechnology industry.
Is TMS Co's EV-to-EBIT too high?
TMS Co's current EV-to-EBIT is -5.49. Based on the distribution chart, TMS Co ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TMS Co has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TMS Co ranks #999999 out of 376 companies for EV-to-EBIT. This places TMS Co in the lower half of its industry. The industry median EV-to-EBIT is 16.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TMS Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMS Co's current EV-to-EBIT is -5.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current EV-to-EBIT of -5.49. The current EV-to-EBIT is -5.49. TMS Co's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For TMS Co (TSE:4891), the current EV-to-EBIT is -5.49 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
32GF Score
Get the complete analysis for TSE:4891
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4891 has been successfully added to your 
